Tassi, Renata A <br/><br/>
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.  [electronic resource] 

 -  Journal of experimental & clinical cancer research : CR  05 2017 
 - 63 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1756-9966 
<br/><br/><label>Standard No.: </label>10.1186/s13046-017-0536-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor<br/>Carcinoma, Ovarian Epithelial<br/>Cell Line, Tumor<br/>Cell Movement<br/>Cell Proliferation<br/>Cell Transformation, Neoplastic--genetics<br/>Cystadenocarcinoma, Serous--genetics<br/>DNA Repair<br/>Disease Progression<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Forkhead Box Protein M1--genetics<br/>Gene Expression Profiling<br/>Gene Expression Regulation, Neoplastic<br/>Gene Knockdown Techniques<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Prognosis<br/>Protein Isoforms<br/>RNA, Small Interfering--genetics